Coronavirus outbreak highlighted vulnerabilities in medical manufacturing supply chain: Fitch Solutions
With pharmaceutical supply chains under immense pressure due to COVID-19, China's role as a global ingredient producer has come under scrutiny, Fitch Solutions has said
New Delhi: With pharmaceutical supply chains under immense pressure due to COVID-19, China's role as a global ingredient producer has come under scrutiny, Fitch Solutions has said.
As per the report, as trade war has heightened discussion over the national security implications of manufacturing new technologies abroad, COVID-19 has highlighted vulnerabilities in the medical manufacturing supply chain, most notably in the US.
Click here to follow LIVE updates on coronavirus outbreak
Related Articles
"We believe that over the longer term, governments may aim to source more key pharmaceutical ingredients locally as opposed to the current heavy reliance on China, and to a lesser degree India," it said.
Representational image. AP
This provides an opportunity for the Indian government to escalate domestic production of pharmaceutical ingredients to counteract an over-reliance on Chinese imports now hampered by COVID-19 shutdowns.
Click here to follow LIVE news and updates on stock markets
The Indian government has aggressively begun implementing a policy to ramp-up local output and emerge as an alternate to China, it said.
As well, growing political will amongst major developed economies could encourage governments to offer incentives for companies to re-shore some medical equipment manufacturing.
A large number of active pharmaceutical ingredients (APIs), or bulk drugs, that are used for the manufacturing of drugs are exported from China.
India for instance imports almost 70 percent of its bulk drugs and intermediates from China.
India relies on bulk ingredients from China to manufacture a fifth of the global supplies of drugs that are off patents.
For India, the pandemic triggered raw material shortages and exposed its dependence on Chinese imports.
"Outside India, in the US as of August 2019, only 28 percent of the manufacturing facilities making APIs to supply the US market were in the country. By contrast, the remaining 72 percent of the API manufacturers supplying the US market were overseas, and 13 percent are in China," the report said.
also read
Chinese technicians and engineers may get faster visas for work in India
The demand of exporters for issuing faster visas for technicians and engineers from China who are required to visit India to set up factories or machinery here, will be taken up with the relevant ministry for faster resolution, according to report.
End of Work from Home? Are TCS employees being forced to come to office?
TCS has begun delivering notes to staff members who don't put in at least 12 days of in-office work each month. The IT company reportedly threatened employees with disciplinary action if they failed to abide by its new policy. The firm is just one of the many that has put an end to work from home
Explained: How the World Health Organisation aims to fight pandemics in the future
Negotiations on new rules for dealing with pandemics are underway at the World Health Organisation. A new pact is a priority for WHO chief who called it a ‘generational commitment that we will not go back to the old cycle of panic and neglect’ at the UN agency's annual assembly